Drug intelligence / Profile preview

KT-A832

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intrapancreatic

Overview

**KT-A832** is an investigational AAV-based gene therapy developed by Kriya Therapeutics for type 1 diabetes. Administered via intrapancreatic injection, it delivers a gene encoding modified insulin-like growth factor 1 (IGF-1) to enable local production of this protein in the pancreas, aiming to restore insulin sensitivity and beta cell function in a durable, one-time treatment. The program leverages Kriya's platform for prevalent diseases, with preclinical status as of available data.[1][4][6]

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on KT-A832.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT-A832.

Explore the full profile